U.S. Court of Appeals for the Federal Circuit
Merck Sharp & Dohme B v. v. Aurobindo Pharma USA, Inc.
This writing
- Type
- Opinion
- Filed
- March 13, 2025
- Case
- Merck Sharp & Dohme B v. v. Aurobindo Pharma USA, Inc.
- Case status
- Decided
Source No authoring judge could be established for this writing, either from provider metadata or from the signature line of the court's published opinion. Benchlight shows the gap rather than guessing at an author.
Opening text
The first passage of the document, as extracted by the source provider.
Case: 23-2254 Document: 118 Page: 1 Filed: 03/13/2025 United States Court of Appeals for the Federal Circuit ______________________ MERCK SHARP & DOHME B.V., MERCK SHARP & DOHME, LLC, Plaintiffs-Appellees v. AUROBINDO PHARMA USA, INC., AUROBINDO PHARMA LTD., USV PRIVATE LIMITED, GLAND PHARMA LIMITED, MANKIND PHARMA LTD., LIFESTAR PHARMA LLC, FRESENIUS KABI USA, LLC, DR. REDDY'S L…
Source Extract supplied by CourtListener. Benchlight does not host the document — read the authoritative text in the court's own PDF.